BBOT on Nasdaq
BridgeBio Oncology Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $121.2M | $73.1M |
| Total operating expenses | $145.8M | $80.9M |
| Loss from operations | -$145.8M | -$80.9M |
| Interest income | $11.3M | $6.4M |
| Income from transition services agreements | $1.2M | $775.0K |
| Change in fair value of participation right liability | -$725.0K | -$564.0K |
| Other income (expense) | -$35.0K | $0 |
| Total other income (expense), net | $11.8M | $6.6M |
| Net loss | -$134.0M | -$74.3M |
| Net loss per share attributable to common stockholders, basic | -$4.30 | -$5,756.41 |
| Net loss per share attributable to common stockholders, diluted | -$4.30 | -$5,756.41 |
| Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic | 31.1M shares | 12.9K shares |
| Weighted-average number of shares used in computing net loss per share attributable to common stockholders, diluted | 31.1M shares | 12.9K shares |
| General and administrative expenses | $24.6M | $7.8M |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $373.7M | $30.9M | |
| Short-term marketable securities | $51.8M | $124.8M | |
| Receivables from related parties | $386.0K | $81.0K | |
| Prepaid expense and other current assets | $6.5M | $3.0M | |
| Total current assets | $432.4M | $158.7M | |
| Property and equipment, net | $956.0K | $490.0K | |
| Operating lease right-of-use asset | $2.3M | $0 | |
| Other non-current assets | $12.6M | $5.0M | |
| Restricted cash | $132.0K | $132.0K | |
| Total assets | $448.4M | $164.3M | |
| Accounts payable | $1.4M | $3.1M | |
| Accrued compensation and benefits | $5.7M | $3.8M | |
| Accrued research and development liabilities | $26.0M | $8.3M | |
| Accrued professional services | $674.0K | $655.0K | |
| Payables to related parties | $534.0K | $483.0K | |
| Operating lease liability, current | $522.0K | $0 | |
| Other accrued liabilities | $240.0K | $166.0K | |
| Participation right liability | $0 | $3.1M | |
| Total current liabilities | $35.0M | $19.6M | |
| Operating lease liability, noncurrent | $2.2M | $0 | |
| Total liabilities | $37.3M | $19.6M | |
| Common stock, $0.0001 par value; 500,000,000 and 41,341,250 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 79,991,768 and 28,415 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $8.0K | $0 | |
| Additional paid-in capital | $767.6M | $43.5M | |
| Accumulated deficit | -$356.6M | -$222.5M | |
| Accumulated other comprehensive income | $16.0K | $348.0K | |
| Total stockholders' equity (deficit) | $411.1M | -$178.6M | -$115.6M |
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) | $448.4M | $164.3M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 0 shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 41.3M shares | |
| Common stock, shares issued | 80.0M shares | 28.4K shares | |
| Common shares, shares outstanding | 80.0M shares | 28.4K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$134.0M | -$74.3M |
| Depreciation of property and equipment | $280.0K | $208.0K |
| Stock-based compensation | $5.9M | $4.4M |
| Fair value of common stock issued to related party | $7.8M | $0 |
| Change in fair value of participation right liability | $725.0K | $564.0K |
| Net accretion of premiums on marketable securities | -$1.3M | -$1.5M |
| Amortization of right-of-use assets | $330.0K | $0 |
| Prepaid expense and other currents assets | -$3.4M | -$1.0M |
| Other non-current assets | -$7.6M | -$3.6M |
| Accounts payble | -$1.8M | $2.5M |
| Accrued compensation and benefits | $1.9M | $2.7M |
| Accrued research and development liabilities | $17.7M | $4.9M |
| Accrued professional services | -$102.0K | $518.0K |
| Operating lease liabilities | -$47.0K | $0 |
| Other accrued liabilities | $74.0K | $141.0K |
| Balances due to and from related parties | -$254.0K | $9.4M |
| Net cash used in operating activities | -$113.9M | -$55.0M |
| Maturities of marketable securities | $157.9M | $31.5M |
| Purchases of marketable securities | -$83.9M | -$154.4M |
| Change in related party receivables related to cash pooling arrangement | $0 | $2.4M |
| Purchases of property and equipment | -$606.0K | -$49.0K |
| Net cash provided by (used in) investing activities | $73.3M | -$120.5M |
| Proceeds from reverse recapitalization and PIPE Financing | $373.5M | $0 |
| Payment of deferred transaction costs | -$12.3M | $0 |
| Issuance of Series A redeemable convertible preferred stock | $0 | $5.9M |
| Issuance of Series B redeemable convertible preferred stock, net of issuance costs | $22.2M | $199.3M |
| Contribution from BridgeBio Pharma | $0 | $1.1M |
| Exercise of common stock options for cash | $45.0K | $52.0K |
| Net cash provided by financing activities | $383.4M | $206.3M |
| Net increase in cash, cash equivalents, and restricted cash | $342.8M | $30.7M |
| Settlement of participation right liability upon issuance of Series B redeemable convertible preferred stock | $3.8M | $0 |
| Right-of-use asset recognized in exchange for operating lease liabilities | $2.7M | $0 |
| Unpaid property and equipment included in accounts payable | $140.0K | $0 |
| Deferred de-SPAC transaction costs included in accrued professional services | $123.0K | $0 |
| Conversion of related party payables into Series A redeemable convertible preferred stock issued to BridgeBio Pharma | $0 | $19.7M |
| Deemed contribution from BridgeBio Pharma upon forgiveness of related party payables | $0 | $3.7M |
| Initial recognition of participation right liability in connection with issuance of Series B redeemable convertible preferred stock | $0 | $2.5M |
| Non-cash transfers of property and equipment from BridgeBio Pharma | $0 | $54.0K |
Compare BridgeBio Oncology Therapeutics, Inc. with another company
Former names
- Helix Acquisition Corp. IIDec 20, 2023 to Aug 6, 20252
Recent filings
- Oct 5, 20264
- Oct 5, 20264
- Oct 5, 20264
- Oct 5, 20264
- Sep 14, 20264
- Sep 10, 2026EFFECT
- Sep 8, 20268-K
- Sep 8, 2026EFFECT
- Sep 1, 2026POS AM
- Sep 1, 2026S-3
- Aug 12, 2026424B3
- Aug 11, 20268-K
- Aug 11, 202610-Q
- Jul 6, 20264
- Jul 6, 2026SCHEDULE 13D/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6